H. Michael Shepard

11.1k citations

64 papers · 9.3k indexed · 4 hit papers · h-index 39

Impact in

Oncology top 0.2%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
Radiology, Nuclear Medicine and Imaging top 0.2%
- Monoclonal and Polyclonal Antibodies Research

Papers in

Oncology 46
- HER2/EGFR in Cancer Research 30
- CAR-T cell therapy research 6
Radiology, Nuclear Medicine and Imaging 32
- Monoclonal and Polyclonal Antibodies Research 32

Co-authors: Gail D. Lewis Phillips B M Fendly Paul Carter David V. Goeddel Claire E. Kotts Leonard G. Presta Dennis J. Henner C Gorman
Journals: Molecular and Cellular Biology (7 papers)Proceedings of the National Academy of Sciences (5 papers)Human Gene Therapy (2 papers)The Journal of Experimental Medicine (2 papers)Cell (2 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

H. Michael Shepard

63 papers receiving 8.6k citations

Hit Papers

align trajectories log scale

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu 1992 · 625 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1992 Breast Cancer Research and Treatment
1992 Science
1992 Proceedings of the National Academy of Sciences
1989 Molecular and Cellular Biology

Peers

Countries citing papers authored by H. Michael Shepard

Since Specialization

Citations

This map shows the geographic impact of H. Michael Shepard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Michael Shepard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Michael Shepard more than expected).

Fields of papers citing papers by H. Michael Shepard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Michael Shepard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Michael Shepard. The network helps show where H. Michael Shepard may publish in the future.

Co-authorship network

The 25 scholars most cited alongside H. Michael Shepard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H. Michael Shepard Line = papers co-authored together H. Michael Shepard links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Team that Just Wouldn’t Quit and a New Paradigm in Cancer Drug Discovery Cell ·H. Michael Shepard	2019	2
2	Multiple cancer-specific antigens are targeted by a chimeric antibody receptor on a single cancer cell JCI Insight ·Yanran He, Karin Schreiber, 邢凯旋, Hsueh-Ming Tai, Catharina Steentoft, Jonathan Zerweck, luxin Li, Preeti Sharma, H. Michael Shepard, Avery D. Posey, Carl H. June, Ulla Mandel, Henrik Clausen, Matthias Leisegang, Stephen C. Meredith, David M. Kranz, Hans Schreiber	2019	25
3	Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activityin vitroand in human tumor xenografts Molecular Cancer Therapeutics ·Jay Sarup, Jin Pei, Jose Antonio Olivencia, Xiaomei Bai, Malgorzata Beryt, Cathleen Brdlik, Jeffrey N. Higaki, Brett Jorgensen, Francis W. Lau, Peter F. Lindley, Jim Liu, Irene Ni, 悟清水, Rajendra Kumari, Susan A. Watson, Juan Zhang, H. Michael Shepard	2008	28
4	Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family Journal of Clinical Investigation ·H. Michael Shepard, Cathleen Brdlik, Hans Schreiber	2008	87
5	Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase11Abbreviations: BVdU, (E)-5-(2-bromovinyl)-2′-deoxyuridine; BVdUMP, (E)-5-(2-bromovinyl)-2′-deoxyuridine 5′-monophosphate; NB1011, (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl l-methoxyalaninylphosphoramidate; COSY, correlated spectroscopy; DCI, direct current ionization; DMF, N,N-dimethylformamide; dUMP, 2′-deoxyuridine 5′-monophosphate; ECTA, enzyme-catalyzed therapeutic agent; 5-FU, 5-fluorouracil; 5-FdUMP, 5-fluoro-2′-deoxyuridine 5′-monophosphate; RFU, relative fluorescence units; THF, N5,N10-methylene tetrahydrofolate; TBDMS, tert-butyldimethylsilyl; and TS, thymidylate synthase (EC 2.1.1.45). Biochemical Pharmacology ·Anthoneta Kopong, Michael P. Groziak, Maria V. Sergeeva, Malgorzata Beryt, Christopher R. Boyer, Robert M. Stroud, Peter H. Sayre, John W. Park, Patrick Johnston, Dennis J. Slamon, H. Michael Shepard, Mark D. Pegram	2001	29
6	Enhancement of Adenovirus-Mediated Gene Transfer to Human Bone Marrow Cells Leukemia & lymphoma ·Tsutomu Watanabe, Linda Kelsey, Latifah Kosim Darusman Dan bambang Sapta Purwoko, Charles Kuszynski, Kazuhiko Ino, Dean G. Heimann, Michelle L. Varney, H. Michael Shepard, C Wang, Daniel C. Maneval, James E. Talmadge	1998	11
7	¹⁸⁶ Re-Labeled Antibodies to p185 ^HER2 as HER2-Targeted Radioimmunopharmaceutical Agents: Comparison of Physical and Biological Characteristics with ¹²⁵ I and ¹³¹ I-Labeled Counterparts Cancer Biotherapy and Radiopharmaceuticals ·Claire E. Kotts, Fu Su, Mohammed Abed, Tom Dodd, 仁志西村, M R Shalaby, 俊英鵜藤, David M. Giltinan, Robert W. Schroff, Alan R. Fritzberg, H. Michael Shepard, Dennis J. Slamon, Beth Hutchins	1996	15
8	Purification of a Type 5 Recombinant Adenovirus Encoding Human p53 by Column Chromatography Human Gene Therapy ·Bernard Huyghe, Xiaodong Liu, Suganto Sutjipto, Barry J. Sugarman, Mark Horn, H. Michael Shepard, Carl J. Scandella, Paul Shabram	1995	159
9	Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies Cancer Immunology Immunotherapy ·Gail D. Lewis Phillips, Irene S. Figari, B M Fendly, Wai Lee Wong, Paul Carter, Cori Gorman, H. Michael Shepard	1993	406
10	Inhibition of Human Lung Cancer Cell Line Growth by an Anti-p185HER2 Antibody American Journal of Respiratory Cell and Molecular Biology ·Jeffrey A. Kern, Anette Pettersson, David B. Weiner, Adi F. Gazdar, H. Michael Shepard, B M Fendly	1993	45
11	C‐erbB‐2 oncoprotein in screen‐detected breast carcinoma: An immunohistological study International Journal of Cancer ·منة الله صلاح الدین سراج, Peter C. Taylor, H. Michael Shepard, M Feldmann, H D Sinnett, Sami Shousha	1993	3
12	Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Sciences ·Paul Carter, Leonard G. Presta, C Gorman, John Brady Ridgway, Dennis J. Henner, 千枝子大西, Rose Eghbalian, Claire E. Kotts, 卢继华, H. Michael Shepard Hit paper breakdown →	1992	1483
13	High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment Nature Biotechnology ·Paul Carter, Robert F. Kelley, Maria Luı́sa Rodrigues, Brad Snedecor, 孙学民, Dr Sudarshan. B. G, Wai Lee Wong, Rose Eghbalian, Claire E. Kotts, 卢继华, Maria Yang, James H. Bourell, H. Michael Shepard, Dennis J. Henner	1992	264
14	p185HER2 signal transduction in breast cancer cells Journal of Biological Chemistry ·G K Scott, J. Zouari, Shiobhán Hellberg Falguera, R. M. Johnson, Jay Sarup, 千枝子大西, A. Ullrich, H. Michael Shepard, Christopher C. Benz	1991	83
15	Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Molecular and Cellular Biology ·Rakesh Kumar, H. Michael Shepard, John Mendelsohn	1991	96
16	p185 ^HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor Molecular and Cellular Biology ·Robert M. Hudziak, Gail D. Lewis Phillips, Marcy Winget, B M Fendly, H. Michael Shepard, Axel Ullrich Hit paper breakdown →	1989	559
17	Resistance of tumor cells to tumor necrosis factor Journal of Clinical Immunology ·H. Michael Shepard, Gail D. Lewis Phillips	1988	41
18	Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. The Journal of Experimental Medicine ·Terje Espevik, Irene S. Figari, M R Shalaby, Anne Rosen Jolivet, Gail D. Lewis Phillips, H. Michael Shepard, Michael A. Palladino	1987	405
19	Carboxyterminal Region of Hybrid Leukocyte Interferons Affects Antiviral Specificity DNA ·Arthur E. Franke, H. Michael Shepard, Catherine M. Houck, David W. M. Leung, David V. Goeddel, Richard M. Lawn	1982	21
20	Increased Synthesis in E. coli of Fibroblast and Leukocyte Interferons Through Alterations in Ribosome Binding Sites DNA ·H. Michael Shepard, Elizabeth Yelverton, David V. Goeddel	1982	92

About H. Michael Shepard

H. Michael Shepard is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Immunology and Allergy, Immunology and Molecular Biology, having authored 64 papers that have together received 9.3k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (32 papers), HER2/EGFR in Cancer Research (30 papers), Glycosylation and Glycoproteins Research (14 papers), Immune Response and Inflammation (8 papers), Virus-based gene therapy research (7 papers), interferon and immune responses (6 papers), CAR-T cell therapy research (6 papers) and Cell Adhesion Molecules Research (6 papers). The work is most often cited by research in Oncology (4.8k citations), Radiology, Nuclear Medicine and Imaging (3.8k citations), Immunology (2.0k citations), Immunology and Allergy (508 citations) and Molecular Biology (4.5k citations). H. Michael Shepard has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Gail D. Lewis Phillips, B M Fendly, Paul Carter, David V. Goeddel, Claire E. Kotts, Leonard G. Presta, Dennis J. Henner, C Gorman, John Brady Ridgway and M R Shalaby. Their work appears in journals such as Molecular and Cellular Biology, Proceedings of the National Academy of Sciences, Human Gene Therapy, The Journal of Experimental Medicine and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact